Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr
Standard
Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr. / Subotic, U; Hosie, S; Waag, K L; Reinshagen, K.
in: KLIN PADIATR, Jahrgang 220, Nr. 4, 26.07.2008, S. 248-52.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Behandlung von Lymphangiomen mit Picibanil im ersten Lebensjahr
AU - Subotic, U
AU - Hosie, S
AU - Waag, K L
AU - Reinshagen, K
PY - 2008/7/26
Y1 - 2008/7/26
N2 - BACKGROUND: The therapeutic gold standard of cystic hygroma is its complete resection. Because of its growth pattern and its main location in the head and neck region complete resection is not always possible. An alternative is the local injection of Picibanil, but only few cases have been published about its use in infants.PATIENTS/METHOD: We retrospectively analyzed the data of 8 infants (age: 2 weeks-12 months) who got Picibanil therapy because of cystic hygroma in the time period 2002 until 2006. Follow up ranged from 3 months up to 3 years.RESULTS: During the postoperative period all patients had local swelling, in 4 cases accompanied with local inflammation and fever. Tumor reduction of >50% was obtained in 7 of 8 patients.CONCLUSIONS: Local injection of Picibanil in infants with cystic hygroma seems to be a safe alternative to surgical therapy, especially when complete tumor resection means damage of important neighbouring structures. Prospective trials are necessary to confirm the better outcome after therapy with Picibanil compare to primary surgery.
AB - BACKGROUND: The therapeutic gold standard of cystic hygroma is its complete resection. Because of its growth pattern and its main location in the head and neck region complete resection is not always possible. An alternative is the local injection of Picibanil, but only few cases have been published about its use in infants.PATIENTS/METHOD: We retrospectively analyzed the data of 8 infants (age: 2 weeks-12 months) who got Picibanil therapy because of cystic hygroma in the time period 2002 until 2006. Follow up ranged from 3 months up to 3 years.RESULTS: During the postoperative period all patients had local swelling, in 4 cases accompanied with local inflammation and fever. Tumor reduction of >50% was obtained in 7 of 8 patients.CONCLUSIONS: Local injection of Picibanil in infants with cystic hygroma seems to be a safe alternative to surgical therapy, especially when complete tumor resection means damage of important neighbouring structures. Prospective trials are necessary to confirm the better outcome after therapy with Picibanil compare to primary surgery.
KW - Antineoplastic Agents
KW - Chemotherapy, Adjuvant
KW - Chylothorax
KW - Combined Modality Therapy
KW - Female
KW - Head and Neck Neoplasms
KW - Humans
KW - Infant
KW - Infant, Newborn
KW - Injections, Intralesional
KW - Lymphangioma, Cystic
KW - Male
KW - Neoplasm Recurrence, Local
KW - Picibanil
KW - Postoperative Complications
KW - Retrospective Studies
KW - English Abstract
KW - Journal Article
U2 - 10.1055/s-2008-1073158
DO - 10.1055/s-2008-1073158
M3 - SCORING: Zeitschriftenaufsatz
C2 - 18654945
VL - 220
SP - 248
EP - 252
JO - KLIN PADIATR
JF - KLIN PADIATR
SN - 0300-8630
IS - 4
ER -